Wednesday, 26 August 2026European Markets

ALAN ALLMAN Stock 9.84% Up On Thursday

Loading stream...

(vianews) - the market ended the session with alan allman (aaa.pa) rising 9.84% to €9.38 on thursday while cac 40 jumped 0.11% to €7,139.25.

alan allman's last close was €8.54, 46.96% below its 52-week high of €16.10.

about alan allman

alan allman associates provides management consulting services. the company provides research and consulting services to other organizations and primarily serves organizations providing consulting services to various sectors. it was founded in 2009 and is based in issy-les-moulineaux, france.

dividend yield

according to morningstar, inc., the next dividend payment is on jun 28, 2022, the estimated forward annual dividend rate is 0.05 and the estimated forward annual dividend yield is 0.51%.

moving average

alan allman's value is under its 50-day moving average of €9.50 and way below its 200-day moving average of €10.57.

volume

today's last reported volume for alan allman is 281 which is 86.55% below its average volume of 2090.

volatility

alan allman's last week, last month's, and last quarter's current intraday variation average was a negative 2.55%, a negative 0.07%, and a positive 2.17%.

alan allman's highest amplitude of average volatility was 3.71% (last week), 1.77% (last month), and 2.17% (last quarter).

more news about alan allman (aaa.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com